CDKI-73
CDKI-73 is a highly potent and selective CDK9 inhibitor (Ki = 4 nM) with significant toxicity toward chronic lymphocytic leukemia (CLL) cells in vitro. Its mechanism involves inducing apoptosis and synergizing with chemotherapeutics like cisplatin, highlighting its research utility in oncology and hematology for studying transcription-dependent cancers.
Product Specifications
CAS Number
1421693-22-2
Product Name Alternative
CDK9, CDKI 73, CDKI73, CDKI-73, CDK7, CDK6, CDK4, CDK2, CLL, CDK1, CDK, Cyclin dependent kinase, AML, Apoptosis, Acute, inhibit, Inhibitor, LS007, LS-007, LS 007, low, myeloid, endosome, leukemia, toxicity
Field of Research
Cell Biology
Purity
95.88% (May vary between batches)
Solubility
DMSO:52 mg/mL (131.83 mM) ;10% DMSO+40% PEG300+5% Tween-80+45% Saline:2.5 mg/mL (6.34 mM)
Smiles
CNc1nc (C) c (s1) -c1nc (Nc2cccc (c2) S (N) (=O) =O) ncc1F
Molecular Formula
C15H15FN6O2S2
Molecular Weight
394.45
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LS119392-20ug 20 µg
C10orf78 (SFR1) (NM_001002759) Human Over-expression Lysate
Sign In for Pricing
View Details 
033396-AP 200 µL
CCNB3, phosphorylated (T280) (CCNB3, CYCB3, G2/mitotic-specific cyclin-B3) (AP) discontinued
Sign In for Pricing
View Details